A Review of Modern Imaging Landscape for Prostate Cancer: A Comprehensive Clinical Guide

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Feb 11

PMID 36769834

Authors

Paul Gravestock

Bhaskar Kumar Somani

Theodoros Tokas

Bhavan Prasad Rai

Affiliations

Soon will be listed here.

Abstract

The development of prostate cancer imaging is rapidly evolving, with many changes to the way patients are diagnosed, staged, and monitored for recurrence following treatment. New developments, including the potential role of imaging in screening and the combined diagnostic and therapeutic applications in the field of theranostics, are underway. In this paper, we aim to outline the current landscape in prostate cancer imaging and look to the future at the potential modalities and applications to come.

Citing Articles

Peptide PET Imaging: A Review of Recent Developments and a Look at the Future of Radiometal-Labeled Peptides in Medicine.

Shabsigh M, Solomon L Chem Biomed Imaging. 2024; 2(9):615-630.

PMID: 39474267 PMC: 11503725. DOI: 10.1021/cbmi.4c00030.

References

Bass E, Pantovic A, Connor M, Loeb S, Rastinehad A, Winkler M . Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2021; 25(2):174-179. PMC: 9184263. DOI: 10.1038/s41391-021-00449-7. View

Afshar-Oromieh A, Zechmann C, Malcher A, Eder M, Eisenhut M, Linhart H . Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2013; 41(1):11-20. PMC: 3843747. DOI: 10.1007/s00259-013-2525-5. View

Russo F, Mazzetti S, Regge D, Ambrosini I, Giannini V, Manfredi M . Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men. Eur Urol Oncol. 2021; 4(6):855-862. DOI: 10.1016/j.euo.2021.03.007. View

Partin A, Mangold L, Lamm D, Walsh P, Epstein J, Pearson J . Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001; 58(6):843-8. DOI: 10.1016/s0090-4295(01)01441-8. View

Morawitz J, Kirchner J, Lakes J, Bruckmann N, Mamlins E, Hiester A . PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications. Eur J Radiol. 2021; 136:109556. DOI: 10.1016/j.ejrad.2021.109556. View

Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A . Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 36(5):446-453. DOI: 10.1200/JCO.2017.75.4853. View

Leitsmann C, Uhlig A, Bremmer F, Mut T, Ahyai S, Reichert M . Impact of mpMRI targeted biopsy on intraoperative nerve-sparing (NeuroSAFE) during robot-assisted laparoscopic radical prostatectomy. Prostate. 2021; 82(4):493-501. DOI: 10.1002/pros.24295. View

Hofman M, Lawrentschuk N, Francis R, Tang C, Vela I, Thomas P . Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020; 395(10231):1208-1216. DOI: 10.1016/S0140-6736(20)30314-7. View

Martin R, Donovan J, Turner E, Metcalfe C, Young G, Walsh E . Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. JAMA. 2018; 319(9):883-895. PMC: 5885905. DOI: 10.1001/jama.2018.0154. View

10.

Moore C, Giganti F, Albertsen P, Allen C, Bangma C, Briganti A . Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force. Eur Urol. 2016; 71(4):648-655. DOI: 10.1016/j.eururo.2016.06.011. View

11.

Barral M, Lefevre A, Camparo P, Hoogenboom M, Pierre T, Soyer P . In-Bore Transrectal MRI-Guided Biopsy With Robotic Assistance in the Diagnosis of Prostate Cancer: An Analysis of 57 Patients. AJR Am J Roentgenol. 2019; 213(4):W171-W179. DOI: 10.2214/AJR.19.21145. View

12.

Margel D, Bernstine H, Groshar D, Ber Y, Nezrit O, Segal N . Diagnostic Performance of Ga Prostate-specific Membrane Antigen PET/MRI Compared with Multiparametric MRI for Detecting Clinically Significant Prostate Cancer. Radiology. 2021; 301(2):379-386. DOI: 10.1148/radiol.2021204093. View

13.

van der Leest M, Cornel E, Israel B, Hendriks R, Padhani A, Hoogenboom M . Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large.... Eur Urol. 2018; 75(4):570-578. DOI: 10.1016/j.eururo.2018.11.023. View

14.

Evangelista L, Zattoni F, Cassarino G, Artioli P, Cecchin D, Dal Moro F . PET/MRI in prostate cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2020; 48(3):859-873. PMC: 8036222. DOI: 10.1007/s00259-020-05025-0. View

15.

Giovanella L, Castellani M, Suriano S, Ruberto T, Ceriani L, Tagliabue L . Multi-field-of-view SPECT is superior to whole-body scanning for assessing metastatic bone disease in patients with prostate cancer. Tumori. 2011; 97(5):629-33. DOI: 10.1177/030089161109700515. View

16.

Basourakos S, Alshak M, Lewicki P, Cheng E, Tzeng M, DeRosa A . Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis. Eur Urol Open Sci. 2022; 37:53-63. PMC: 8883190. DOI: 10.1016/j.euros.2022.01.001. View

17.

Castellani D, Pirola G, Law Y, Gubbiotti M, Giulioni C, Scarcella S . Infection Rate after Transperineal Prostate Biopsy with and without Prophylactic Antibiotics: Results from a Systematic Review and Meta-Analysis of Comparative Studies. J Urol. 2021; 207(1):25-34. DOI: 10.1097/JU.0000000000002251. View

18.

Eldred-Evans D, Ahmed H . Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography-The IP1-PROSTAGRAM Study-Reply. JAMA Oncol. 2021; 7(10):1575-1576. DOI: 10.1001/jamaoncol.2021.2967. View

19.

Desai S, Costa D . PI-RADS and Likert scales for structured reporting in multiparametric MR imaging of the prostate. Br J Radiol. 2021; 95(1131):20210758. PMC: 8978252. DOI: 10.1259/bjr.20210758. View

20.

Shen G, Deng H, Hu S, Jia Z . Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 2014; 43(11):1503-13. DOI: 10.1007/s00256-014-1903-9. View